BRCA1 and breast carcinoma: Our findings thus provide insights into the role of macrophages in PARPi therapy and demonstrate a mechanism underlying PARPi resistance that is mediated through bi-directional interactions between tumor cells and immune cells in BRCA1-deficient breast cancers (Fig. 7).